43 results about "Thioredoxin" patented technology

The invention relates to a wheat stem rot regulatory gene Tatrx-m, and an encoding protein, a recombinant vector and an application of the wheat stem rot regulatory gene Tatrx-m. The genomic sequence of the gene is SEQ ID NO.1, the CDS sequence of the gene is SEQ ID NO.2, and thioredoxin shown as SEQ ID NO.3 is encoded. The invention further provides a specific primer pair used for gene identification, a silent vector (Tatrx-m-VIGS) and an overexpression vector (LGY-OE3-Tatrx-m) are constructed, and the function of the primer pair is verified through a virus-induced gene silencing (VIGS) technology and agrobacterium-mediated transformation of wheat. Experiments show that silence of Tatrx-m results in significant reduction of wheat stem rot resistance, and overexpression of the gene can improve resistance. Based on hypha quantification, DAB staining, H2O2 content and cell death analysis, Tatrx-m is revealed to enhance wheat resistance by regulating active oxygen removal and cell wall strengthening pathways. The gene TaTrx-m has the positive regulation effect in wheat stem rot for the first time, can be applied to disease-resistant molecular marker development, gene editing and transgenic breeding, provides core genetic resources for disease-resistant variety breeding, and has theoretical and application values.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention belongs to the technical field of cosmetics, and particularly relates to a cell energy activation composition with an anti-aging effect and a preparation method thereof, the cell energy activation composition with the anti-aging effect and the preparation method thereof are characterized in that the cell energy activation composition with the anti-aging effect comprises the following components: 3-10 parts of thiotaurine and 0.01-0.5 part of a metal ion compound, the composition is prepared from the following raw materials in parts by weight: 0.05-0.5 part of an antioxidant, 0.005-0.05 part of redox regulatory protein, 0.1-6 parts of a raw grass-containing extract, 0.01-1 part of 4-tert-butyl cyclohexanol and 0.05-3 parts of a lipidosome delivery system, according to the invention, multi-channel energy activation is carried out: thiotaurine participates in energy metabolism, metal ions promote enzyme activity, thioredoxin maintains redox balance, and mitochondrial functions are comprehensively improved; liposomal delivery enhances absorption: the transdermal ability of active matters is improved, the stability is enhanced, and the utilization rate is increased; multiple anti-aging mechanisms are as follows: oxidation resistance, saccharification resistance and cell repair.

The invention relates to the technical field of genetic engineering, and discloses a genetically engineered bacterium for producing beta-ionone at high yield and application of the genetically engineered bacterium. A synthetic biological plasmid modularization technology is adopted, coding genes of carotenoid cleavage dioxygenase NtCCD1 in tobacco are excavated, and specific soluble protein tags including a thioredoxin tag, a maltose binding protein tag and a glutathione transferase tag are screened, so that the content of the carotenoid cleavage dioxygenase NtCCD1 in the tobacco is determined. The NtCCD1 is subjected to single-point mutation modification of mutation of 431st-site histidine into tyrosine, lysine or glutamine, and the fermentation enzyme and the gene engineering bacterium which can efficiently catalyze splitting decomposition of beta-carotene in tobacco to produce beta-ionone are constructed. The biosynthesis of the tobacco aroma component beta-ionone is realized, and the method has high efficiency.

This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.

This invention relates to the field of gene editing, and in particular to a very small CRISPR / Cas12hacker gene cutting system. The CRISPR / Cas12 gene cutting system includes a Cas12hacker nuclease or a polynucleotide encoding the Cas12hacker nuclease, and also includes guide RNA or a polynucleotide encoding the guide RNA. By binding to the host factor thioredoxin TrxA, the CRISPR-Cas12 gene cutting system enhances the efficiency of the Cas12hacker nuclease in precisely cutting double-stranded DNA, thereby achieving genomic DNA double-strand breaks and highly efficient in vitro DNA double-strand cutting.

Disclosed are a thioredoxin mutant, preparation method thereof, and application thereof in production of recombinant fusion protein. The thioredoxin mutant is prepared by modifying at least one amino acid in the amino acid sequence of SEQ ID NO: 1.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to bacteriophage-tolerant escherichia coli and application of the bacteriophage-tolerant escherichia coli in the field of L-tryptophan synthesis. Specifically, the escherichia coli is obtained at least by knocking out a trxA gene for coding thioredoxin in an original strain, carrying out site-specific modification on FhuA protein, and knocking out a trpR gene for coding L-tryptophan operon repressor protein and a tnaA gene for coding tryptophan enzyme. Genetic engineering modification is performed on wild escherichia coli based on a genetic engineering technology, so that the escherichia coli genetically engineered bacterium tolerant to the bacteriophage is finally obtained, and meanwhile, the utilization rate of glucose can be remarkably improved, so that the L-tryptophan synthesis level is relatively high, and the application prospect is wide. And the method can be expanded and applied to microbial fermentation of other various high-added-value compounds, so that the method has a good practical application value.

The invention relates to methods of inhibiting hair growth in a subject, the method comprises administering an inhibitor of lactic acid fermentation to the subject, wherein the inhibitor is selected from the group consisting of pyruvate dehydrogenase kinase inhibitor, desoxyrhapontigenin, a phosphofructokinases inhibitor, a thioredoxin-1 inhibitor, L- Asparaginase, a GLUT1 inhibitor, a glutaminase C inhibitor, a hexokinase inhibitor and an mTORCI and mTORC2 inhibitor. Also provided herein are compositions for inhibiting hair growth and methods of screening for inhibitors of hair growth.

The application belongs to the technical field of genetic engineering. The application provides application of a thiol-oxidoreductase in promoting keratin enzymolysis and a method for promoting keratin enzymolysis. The thiol-oxidoreductase is applied to a keratin enzymolysis system, and the enzymolysis effect is obviously improved. Through testing, the enzymolysis effect of the thiol-oxidoreductase combined with a protease on keratin is not only obviously higher than the enzymolysis effect of a single protease, but also is better than the hydrolysis of keratin by a chemical reducing agent with the same concentration. The application retains the advantages of enzyme method "green chemistry" and is friendly to the environment.

The invention belongs to the technical field of biology, and particularly relates to a thioredoxin mutant as well as a preparation method and application thereof. The mutant with high antioxidant activity is obtained by carrying out combined mutation on wild thioredoxin, the mutant has outstanding advantages in improving the expression quantity, is good in solubility, has relatively strong antioxidant activity and anti-inflammatory and soothing effects, can be applied to skin care and washing care products by being combined with other raw materials and auxiliary materials, and has a wide application prospect. The compound is a brand-new efficient active raw material.

This invention discloses a compound seed treatment agent containing metalaxyl-M and tebuconazole, its preparation method, and its uses, belonging to the technical field of seed treatment agents. The suspension of this invention uses metalaxyl-M, tebuconazole, and sodium selenite as the main components, supplemented with emulsifying and dispersing agents, wetting and dispersing agents, antifreeze agents, suspending agents, film-forming agents, and warning colors, and is prepared by adding deionized water to a sufficient volume. Metalaxyl-M targets and inhibits ribosomal RNA polymerase I of oomycete pathogens, while tebuconazole targets and inhibits sterol 14α-demethylase. The two have complementary fungicidal spectra, synergistically controlling maize stalk rot and maize head smut. Sodium selenite, by inhibiting the oxidative stress defense system of pathogenic fungi involving glutathione and thioredoxin, promotes the effects of the two main components and simultaneously remediates selenium-deficient soils. This invention is suitable for the green and efficient control of maize stalk rot and head smut, and also has the function of ecological restoration of selenium-deficient soils.

The invention relates to a piperidine derivative as shown in a formula (I), and an isotope form, a stereoisomer, a tautomer, a cis-trans-isomer, pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a hydrate, a prodrug and a polymorphic substance of the piperidine derivative. The compound has a good application prospect in the aspect of preparing medicines for preventing and / or treating TXNIP activity mediated diseases.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX) engineered to synthesize DNA with reduced stutter artifacts in the absence of a reducing agent. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein and methods of use thereof in the absence of a reducing agent are also within the scope herein.

The invention belongs to the field of biotechnology and medicine, provides application of thioredoxin TXN1 and TRP14 as a bidirectional switch for regulating and controlling a cell death mode and application of an anti-cancer drug, and particularly relates to new application of TXN1 and TRP14. The invention reveals that TXN1 and TRP14 play a role of a bidirectional regulation switch in regulating the sensitivity of non-small cell lung cancer cells to different programmed death modes (including apoptosis, ferroptosis and disulfide death) for the first time. By reducing the activity or expression of TXN1 or TRP14, the sensitivity of cancer cells to apoptosis inducers and ferroptosis inducers can be enhanced, but the resistance of the cancer cells to glucose deprivation-induced disulfide death is remarkably enhanced. The discovery shows that inhibition of TXN1 / TRP14 can be combined with an apoptosis / ferroptosis inducer to treat cancers; meanwhile, an inhibitor aiming at TXN1 / TRP14 can be used for preventing or treating diseases related to disulfide death. The invention provides a cancer treatment composition based on the discovery, a drug screening method and biomarker application.

The present invention relates to the production of a protease-based protein biosensor capable of specifically quantifying methionine sulfoxide present in a target protein and use thereof, and more specifically, to: a recombinant protein for a fluorescent biosensor for quantifying methionine sulfoxide present in a target protein, the recombinant protein comprising a fluorescent protein, a methionine sulfoxide reductase (Msr) protein, an enterokinase cleavage site, a thioredoxin protein, and protein G; a biosensor comprising same; and a method for quantifying methionine sulfoxide in a target protein using same. The biosensor according to the present invention can accurately measure in a quantitative manner the degree of oxidation of methionine residues in a specific protein rather than all proteins through the detection of specific fluorescence changes, and thus can be used as a fluorescent biosensor for diagnosing oxidative stress diseases. Moreover, the biosensor can recognize the degree of aging through the measurement of the degree of oxidation, and thus can be effectively used for diagnosing aging and related diseases.

The present invention relates to the field of biomedical technologies, and more specifically to a modified mRNA vaccine against tetanus and its preparation method. A modified mRNA vaccine against tetanus, characterized in that: the vaccine comprises: (1) mRNA for expressing a tetanus toxin immunogen, the immunogen being one of an Hc protein, an Hc-TRX protein, and an Hn+Hc protein; (2) a vaccine carrier, the vaccine carrier being a liposome nanoparticle that can be utilized by the mRNA. The main advantages of the present invention are: (1) for the first time, the C-terminal domain of the heavy chain of tetanus toxin (Hc), the fusion protein of the C-terminal domain of the heavy chain and thioredoxin (TRX-Hc), and the complete heavy chain of tetanus toxin (Hn+Hc) are selected as antigens to develop a modified mRNA vaccine; (2) the three developed tetanus toxin mRNA vaccines can all effectively induce specific antibody responses.

This invention discloses the application of a rubber tree thioredoxin or related biomaterials, belonging to the field of biotechnology, for improving the resistance of rubber trees to low temperature and oxidative stress at the molecular level. The amino acid sequence of thioredoxin is shown in SEQ ID NO. 5. Experiments have shown that expression of the gene encoding this thioredoxin in yeast enhances the cold resistance and antioxidant capacity of recombinant yeast. Therefore, the gene encoding this thioredoxin can be used to improve the cold resistance and antioxidant capacity of plants or microorganisms.

Disclosed are compositions and methods for decreasing the viscosity and / or cohesiveness of and / or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.

The invention discloses application of rubber tree thioredoxin or a biological material related to thioredoxin, belongs to the technical field of biology, and is used for improving the resistance of rubber trees to low temperature and oxidative stress from the molecular level. The amino acid sequence of the thioredoxin is as shown in SEQ ID NO. 5. Experiments prove that the cold resistance and oxidation resistance of recombinant yeast can be improved by expression of the encoding gene of the thioredoxin in the yeast. Therefore, the encoding gene of the thioredoxin can be used for improving cold resistance and oxidation resistance of plants or microorganisms.

The invention discloses an antibody for resisting thioredoxin, and relates to the field of antibodies. The anti-thioredoxin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, can be specifically bound with thioredoxin, has good binding activity and stability, and is wide in application and good in application prospect.

The application discloses a combined drug for treating prostate cancer and application, the combined drug is a combined drug of FEN1-IN-4 and TRi-1 administered respectively or simultaneously, the FEN1-IN-4 is an inhibitor targeting Flap endonuclease 1, and the TRi-1 is an inhibitor targeting thioredoxin (TXN) antioxidant system.The combined treatment scheme of FEN1-IN-4 and TRi-1 provided by the application firstly shows a strong antitumor effect superior to single drug in vitro experiment.FEN1-IN-4 as FEN1 specific inhibitor can block the endonuclease function of FEN1 by combining with the active site of FEN1, and can achieve significant growth inhibition to various prostate cancer cell lines such as LNCaP, 22RV-1, PC3, DU145, and the like, and TRi-1 as TXN antioxidant system inhibitor can target to destroy the oxidative stress balance of tumor cells, and the two act on different key pathways (DNA replication / damage repair pathway and antioxidant defense pathway) of tumor cells, forming a "double targeting" synergistic effect.

The present invention addresses a first problem of providing a new liposome dispersion containing thioredoxin. When a saccharomyces / rice fermentation liquid extract that contains thioredoxin is dispersed in an aqueous solvent, turbidity having non-uniform light transmittance occurs therein. The occurrence of turbidity means the precipitation of a component, and potentially leads to a reduction in the pharmaceutical effect of the component. In addition, the occurrence of turbidity potentially leads to a reduction in stability due to uneven aggregation. The present invention addresses a second problem of inhibiting turbidity that occurs when a saccharomyces / rice fermentation liquid extract that contains thioredoxin is dispersed in an aqueous solvent. As a solution to said problems, provided is a liposome dispersion containing thioredoxin or containing a saccharomyces / rice fermentation liquid extract that contains thioredoxin.

The invention discloses a combined medicine for treating prostatic cancer and application, the combined medicine is a combined medicine of FEN1-IN-4 and TRI-1 which are respectively or simultaneously administered, the FEN1-IN-4 is an inhibitor of a targeted Flap endonuclease 1, and the TRI-1 is an inhibitor of a targeted thioredoxin (TXN) antioxidant system. According to the combined treatment scheme of FEN1-IN-4 and TRI-1 provided by the invention, firstly, a strong anti-tumor effect superior to that of a single drug is shown in an in-vitro experiment; the FEN1-IN-4 serving as a FEN1 specific inhibitor can block the endonuclease function of the FEN1 active site by combining the FEN1 active site and can achieve remarkable growth inhibition on various prostate cancer cell lines such as LNCaP, 22RV-1, PC3 and DU145, and the TRI-1 serving as a TXN antioxidant system inhibitor can achieve remarkable growth inhibition on various prostate cancer cell lines such as LNCaP, 22RV-1, PC3 and DU145. Oxidative stress balance of tumor cells can be damaged in a targeted mode, and the two functions on different key pathways (a DNA replication / damage repair pathway and an anti-oxidation defense pathway) of the tumor cells to form a dual-targeting synergistic effect.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX) engineered to synthesize DNA with reduced stutter artifacts in the absence of a reducing agent. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein and methods of use thereof in the absence of a reducing agent are also within the scope herein.

Methods for treating and / or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and a thioredoxin (TRX), wherein one or both of TRX and TBD are fused or otherwise bound to the DNA polymerase domain. The TRX or TBD may also be provided as a separate entity in the system herein (e.g., a binary system). The DNA polymerase / TBD / TRX compositions and systems herein are engineered to reduce lagging and / or to produce less lagging artifacts. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein and methods of use thereof are also within the scope of herein.

The present application relates to a kind of molecular chaperone, nano-carrier and its preparation method and application.The molecular chaperone is the recombinant histidine-sulphur oxygen protein coupled with single-stranded DNA, and the cysteine residue is introduced in the protein and coupled with the single-stranded DNA of amino modification.The nano-carrier is DNA tetrahedron, and the DNA tetrahedron is obtained by self-assembly based on base pairing principle from multiple DNA single strands.DNA nano-carrier is used to deliver the molecular chaperone, can realize HTrX to specific subcellular compartment, i.e.the targeted delivery of ribosome, so that the protein in ribosome exerts biological effect, reduces the negative influence of oxidative stress on protein synthesis to reverse the aging process.The present application also discloses the application of the above-mentioned molecular chaperone and nano-carrier in preparing anti-aging drugs.

The invention provides a mu-conopeptide fusion protein and a preparation method of mu-conopeptide, and belongs to the technical field of biology. The invention provides a [mu]-conopeptide fusion protein. The [mu]-conopeptide fusion protein comprises a folded protein in a connected state and [mu]-conopeptide which is repeatedly connected in series, the folded protein comprises thioredoxin and disulfide bond isomerase; the amino acid sequence of the mu-conopeptide is as shown in SEQ ID NO: 1. According to the method disclosed by the invention, the thioredoxin and the disulfide bond isomerase are used as folding proteins, so that the tandem expressed mu-conopeptide can correctly and effectively form the mu-conopeptide with three pairs of disulfide bonds, and the method can effectively improve the yield of the mu-conopeptide. In addition, the [mu]-conopeptide fusion protein can be used for biosynthesizing [mu]-conopeptide, and compared with a traditional method, the [mu]-conopeptide fusion protein is more environmentally friendly, lower in cost compared with solid-phase synthesis and suitable for large-scale production.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX), wherein one or both of the TRX and TBD are fused or otherwise conjugated to the DNA polymerase domain. The TRX or TBD may also be provided as separate entities (e.g., binary systems) in the systems herein. The DNA polymerase / TBD / TRX compositions and systems herein are engineered to reduce stutter and / or produce fewer stutter artifacts. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein, and methods for using the same, are also within the scope of the present specification.